Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

In September 2023, a study led by professor Erlie Jiang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published in Hematological Oncology,  focused on the effectiveness of azacytidine (AZA) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML). Through propensity score matching, the research compared 78 treated patients with 102 historical controls, revealing that AZA significantly improves relapse-free survival without severe adverse effects. This study, by demonstrating the potential of AZA maintenance to reduce relapse in AML patients, marks a significant contribution to the field of hematological oncology and opens new avenues for personalized post-transplant care.
The Composite Immune Risk Score predicts overall survivalafter allogeneichematopoietic stem cell transplantation: A retrospective analysis of 1838 cases

The Composite Immune Risk Score predicts overall survivalafter allogeneichematopoietic stem cell transplantation: A retrospective analysis of 1838 cases

In November 2022, professor Erlie Jiang and his team from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a crucial study in the American Journal of Hematology,  focusing on the impact of the Composite Immune Risk Score on survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Analyzing 1838 cases, the study highlighted the score's potential to predict overall survival, offering a new tool for personalized post-transplant care. This research marks a significant advancement in understanding and managing hematological malignancies, promising to improve patient outcomes.
Outcomes of acute myeloid leukemia patients undergoing allogeneichematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

Outcomes of acute myeloid leukemia patients undergoing allogeneichematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system

In February 2024, professor Erlie Jiang and colleagues from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science published a pivotal study in Experimental Hematology & Oncology , focusing on the validation and enhancement of the 2022 European LeukemiaNet (ELN) genetic risk system for acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation. By analyzing 600 AML patients, the study not only validated the ELN-2022 system against its 2017 version but also improved its prognostic accuracy by incorporating minimal residual disease (MRD) status. This research marks a significant advancement in the personalized treatment planning and prognosis of AML patients